• Explore /
  • Poster
  • / RELATIVITY-106: A phase 1/2 trial of nivolumab (NIVO) + relatlimab (RELA) in combination with bevacizumab (BEV) in first-line (1L) hepatocellular carcinoma (HCC).

RELATIVITY-106: A phase 1/2 trial of nivolumab (NIVO) + relatlimab (RELA) in combination with bevacizumab (BEV) in first-line (1L) hepatocellular carcinoma (HCC).

Abstract Poster

Authors

null

Bruno Sangro

Clínica Universidad de Navarra and CIBEREHD, Pamplona, Spain;

Bruno Sangro , Thomas Yau , James J. Harding , Mirelis Acosta Rivera , Numata Kazushi , Anthony B. El-Khoueiry , Marcia Cruz-Correa , David Perez-Callejo , Sean McLean , Jacy Sparks , Jaclyn Neely , Masatoshi Kudo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05337137

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr TPS636)

DOI

10.1200/JCO.2023.41.4_suppl.TPS636

Abstract #

TPS636

Poster Bd #

P5

Abstract Disclosures

Similar Posters

First Author: Paolo Antonio Ascierto

First Author: Daneng Li

First Author: Robert L. Ferris

First Author: Ming Liu